Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 1

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 1
---
), the issuance of shares of our common
stock, par value $0.0001 per share (the “Common Stock”) underlying the Series A warrants (the “Series A Warrants”)
and Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Series Warrants”),
including by operation of certain anti-dilution provisions contained therein, issued by us in a public offering transaction (the “Offering”)
on February 19, 2025 (including an aggregate of approximately 1,064,846,416.38 shares of Common Stock issuable upon exercise of the Series
Warrants which consists of (i) an aggregate of approximately 81,911,262.80 shares of Common Stock issuable upon exercise of 40,000,000
Series A Warrants issued in the Offering (assuming the full exercise of the Series A Warrants at an exercise price equal to the floor
price of $0.0586) and (ii) an aggregate of approximately 982,935,153.58 shares of Common Stock issuable upon exercise of 40,000,000 Series
B Warrants issued in the Offering (assuming (x) the full exercise of the Series B Warrants at an exercise price equal to the floor price
of $0.0586 and (y) all the Series B Warrants are exercised on the “zero exercise price” basis), (ii) approve an amendment
to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect, at the discretion of the
Board but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders
at the Special Meeting, a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-250
to 1-for-500, with such ratio to be determined by the board of directors of the Company in its discretion and included in a public announcement;
(iii) approve the Third Amendment to the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as
amended, to increase the total number of shares of the Company’s Common Stock authorized for issuance under such plan by 1,000,000,000,
to a total of 1,002,760,000 shares of Common Stock; (iv) approve an amendment to the Company